1,507
Participants
Start Date
April 27, 2021
Primary Completion Date
November 3, 2022
Study Completion Date
February 6, 2023
Prospective observational cohort study
Prospective observational cohort study. No study treatment was administered in this study.
GSK Investigational Site, Beijing
GSK Investigational Site, Beijing
GSK Investigational Site, Shenyang
GSK Investigational Site, Shenyang
GSK Investigational Site, Shanghai
GSK Investigational Site, Shanghai
GSK Investigational Site, Hefei
GSK Investigational Site, Jinan
GSK Investigational Site, Jinan
GSK Investigational Site, Tianjin
GSK Investigational Site, Tianjin
GSK Investigational Site, Hangzhou
GSK Investigational Site, Zhejiang
GSK Investigational Site, Nanchang
GSK Investigational Site, Chongqing
GSK Investigational Site, Chongqing
GSK Investigational Site, Xiangtan
GSK Investigational Site, Wuhan
GSK Investigational Site, Wuhan
GSK Investigational Site, Jingzhou
GSK Investigational Site, Zhengzhou
GSK Investigational Site, Pingdingshan
GSK Investigational Site, Luoyang
GSK Investigational Site, Nanyang
GSK Investigational Site, Shaoguan
GSK Investigational Site, Huizhou
GSK Investigational Site, Shenzhen
GSK Investigational Site, Jiangmen
GSK Investigational Site, Nanning
GSK Investigational Site, Nanning
GSK Investigational Site, Chengdu
GSK Investigational Site, Yibin
GSK Investigational Site, Yibin
GSK Investigational Site, Xi'an
GSK Investigational Site, Xi'an
GSK Investigational Site, Yinchuan
GSK Investigational Site, Taiyuan
GSK Investigational Site, Cangzhou
GSK Investigational Site, Shanxi
Lead Sponsor
GlaxoSmithKline
INDUSTRY